Vertex Pharmaceuticals (WBO:VRTX) Change In Payables And Accrued Expense : €451 Mil (TTM As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Vertex Pharmaceuticals Change In Payables And Accrued Expense?

Vertex Pharmaceuticals's Change In Payables And Accrued Expense for the quarter that ended in Dec. 2023 was €-356 Mil. It means Vertex Pharmaceuticals's Accounts Payable & Accrued Expense declined by €356 Mil from Sep. 2023 to Dec. 2023 .

Vertex Pharmaceuticals's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2023 was €438 Mil. It means Vertex Pharmaceuticals's Accounts Payable & Accrued Expense increased by €438 Mil from Dec. 2022 to Dec. 2023 .

Vertex Pharmaceuticals Change In Payables And Accrued Expense Historical Data

The historical data trend for Vertex Pharmaceuticals's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vertex Pharmaceuticals Change In Payables And Accrued Expense Chart

Vertex Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

135.09

142.62

298.51

626.16

438.42

Vertex Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															-262.34	164.76	288.25	354.09	-356.25

Vertex Pharmaceuticals Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €451 Mil.

Vertex Pharmaceuticals Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Vertex Pharmaceuticals's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Vertex Pharmaceuticals (WBO:VRTX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vertex Pharmaceuticals Inc (WBO:VRTX) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

VRTX:USA VRTX:Mexico 1VRTX:Italy VX1d:UK VX1:Germany VRTX34:Brazil

Address

50 Northern Avenue, Boston, MA, USA, 02210

Website

https://www.vrtx.com

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.